By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    benefits of using protein powder to build muscles
    Protein Powder for Muscle Mass: Everything You Need to Know
    December 12, 2021
    changes brought on by blockchain in healthcare
    Technology In The Healthcare Industry
    March 28, 2022
    What Does Core Body Temperature Say About Health?
    August 17, 2022
    Latest News
    Grounded Healing: A Natural Ally for Sustainable Healthcare Systems
    May 16, 2025
    Learn how to Renew your Medical Card in West Virginia
    May 16, 2025
    Choosing the Right Supplement Manufacturer for Your Brand
    May 1, 2025
    Engineering Temporary Hospitals for Extreme Weather
    April 24, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    FDA Approves Diabetes Pill
    May 2, 2011
    Patient Gets Drunk on Hand Sanitizer
    June 20, 2011
    Cultivating Health Improvement
    July 20, 2011
    Latest News
    Building Smarter Care Teams: Aligning Roles, Structure, and Clinical Expertise
    May 18, 2025
    The Critical Role of Healthcare in Personal Injury Recovery: A Comprehensive Guide for Victims
    May 14, 2025
    The Backbone of Successful Trials: Clinical Data Management
    April 28, 2025
    Advancing Your Healthcare Career through Education and Specialization
    April 16, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Rubigo Therapeutics Develops Early Assessment and Treatment for Skin Cancer
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Diagnostics > Rubigo Therapeutics Develops Early Assessment and Treatment for Skin Cancer
Diagnostics

Rubigo Therapeutics Develops Early Assessment and Treatment for Skin Cancer

HerinaAyot
Last updated: May 25, 2011 3:49 pm
HerinaAyot
Share
5 Min Read
SHARE

There are multiple types of skin disorders that could cause anyone concerned about cancer to wonder about a spot on their skin or on a loved one’s skin.  This fear of having cancer is not unfounded as the incidence of skin cancer is increasing at an alarming rate due in large part by ultraviol

There are multiple types of skin disorders that could cause anyone concerned about cancer to wonder about a spot on their skin or on a loved one’s skin.  This fear of having cancer is not unfounded as the incidence of skin cancer is increasing at an alarming rate due in large part by ultraviolet (UV) exposure either over time or to excessive sun burn.  Rubigo Therapeutics is a development stage biotech company focused on developing a technology using an active polymeric material that offers a topically controlled release of small molecules targeted at tissue lesions suspected of being cancerous and longer term, a therapeutic delivery platform.

Although melanoma is the fifth leading cause of death associated with cancer in men and seventh for women, ahead of ovarian, identifying these types of lesions are not always as easy as everyone would like.  Additionally, even squamous-cell carcinoma, which is typically perceived as benign, can become lethal if not addressed early enough.  Early confirmatory feedback that an odd looking mole or lesion is cancerous can be of tremendous value to patients, physicians and healthcare payers to either objectively dismiss a concern or plan an appropriate, timely course of action.

The list of possible market opportunities and possible drug candidates that could be combined with Rubigo Therapeutics’ unique technology is substantial; however, the company has elected to focus its development efforts in skin cancer involving Imiquimod, an immune response modifier, due to a number of competitive factors.

More Read

In-office radiology
In-Office Imaging for Radiologists: An Uncertain Future
iPhone App Gives Skin Cancer Risk Assessment
How Healthcare Providers Can Help Detect Pre-Ruptured Membranes
The Cost of Diagnosis: The Sometimes Fatal “Incidentaloma”
Cause and Effect – What Leads to a Misdiagnosis?

Imiquimod, which was developed and patented by 3M in the early 90’s and FDA approved in 2006 for genital warts, and subsequently for actinic keratosis and basal cell cancer, has shown clinical effectiveness to the FDA, prescribing physicians and healthcare payers.  This has occurred over the past five years despite a broad array of topical delivery issues, questions involving dosing and adverse effects in patients.  Due to Rubigo Therapeutics’ unique polymer construction, Imiquimod can be easily and consistently loaded and more importantly, delivered in a consistent and reliable fashion transdermally into the patient’s skin where needed.  Early in vitro data suggests this can be done with lower concentrations of the active drug, providing additional control and means to control dosing of the therapeutic molecule than is currently offered by creams.  The company believes that its substantially improved means of delivering a highly effective, market recognized therapeutic molecule for the treatment of skin cancer, both for early assessment and treatment which is protected by fresh intellectual property, makes Rubigo Therapeutics a novel technology entrant in a large, growing worldwide market.

In terms of treatment, all forms of skin cancer can be successfully treated surgically.  From the perspective of healthcare payers such as the Center for Medicaid and Medicare Services (“CMS”) or Private Payer, management of skin cancers are costly and will continue to be costly unless earlier diagnosis and treatment can occur.  Today, non-melanoma and melanoma disorders are estimated to cost as much as $1B and $1.9B per year respectively in the U.S.  Consequently, the need to accelerate earlier assessment of potentially deadly and yet, treatable skin lesions is a very compelling need.  This need is further enhanced when one can improve the information being discussed and utilized between patient and physician to achieve the best clinical outcomes and minimizing surprises and patient dissatisfaction regarding the loss of tissue or worse yet, becoming disfigured.  Rubigo Therapeutics will be a presenting company at OneMedForum NY 2011 June 22-24.

 

TAGGED:diagnosticsRubigo Therapeuticsskin cancer
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

Do You Grind Your Teeth at Night? Here’s How Night Guards and TMJ Treatments Can Help
Do You Grind Your Teeth at Night? Here’s How Night Guards and TMJ Treatments Can Help
Dental health
May 21, 2025
The Secret To A Confident Smile: Top Tips For Better Teeth
The Secret To A Confident Smile: Top Tips For Better Teeth
Dental health
May 21, 2025
Clinical Expertise
Building Smarter Care Teams: Aligning Roles, Structure, and Clinical Expertise
Health care
May 18, 2025
Grounded Healing: A Natural Ally for Sustainable Healthcare Systems
Grounded Healing: A Natural Ally for Sustainable Healthcare Systems
Health
May 15, 2025

You Might also Like

Use of Light Technology Avoids Blood Clotting

March 11, 2011
DiagnosticsWellness

Wake Up: It’s National Sleep Awareness Week

March 5, 2013
find zebra search engine
DiagnosticsRemote Diagnostics

FindZebra: Rare Disease Search Engine

March 23, 2013
healthcare in Brazil
DiagnosticsGlobal Healthcare

Pioneering Healthcare in Brazil

February 26, 2014
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?